Annette E. Hay

3.2k citations

82 papers · 1.6k indexed · 1 hit paper · h-index 15

Impact in

Pathology and Forensic Medicine top 1%
- Lymphoma Diagnosis and Treatment
Oncology top 2%
- CAR-T cell therapy research
- Viral-associated cancers and disorders

Papers in

Pathology and Forensic Medicine 34
- Lymphoma Diagnosis and Treatment 33
Hematology 21
- Multiple Myeloma Research and Treatments 12

Co-authors: Michael Crump John Kuruvilla Liting Zhu Christian Gisselbrecht Éric Van Den Neste Sami Boussetta William Y. Go Lynn Navale
Journals: Blood (21 papers)Journal of Clinical Oncology (9 papers)JNCI Journal of the National Cancer Institute (2 papers)Annals of Oncology (2 papers)The Oncologist (2 papers)
Partner nations: Canada United States Italy

In The Last Decade

Annette E. Hay

69 papers receiving 1.5k citations

Hit Papers

align trajectories log scale

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study 2017 · 1.0k citations

Peers

Countries citing papers authored by Annette E. Hay

Since Specialization

Citations

This map shows the geographic impact of Annette E. Hay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Annette E. Hay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Annette E. Hay more than expected).

Fields of papers citing papers by Annette E. Hay

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Annette E. Hay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Annette E. Hay. The network helps show where Annette E. Hay may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Annette E. Hay, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Annette E. Hay Line = papers co-authored together Annette E. Hay links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Minimal Residual Disease Testing Infrastructure in Multiple Myeloma: Guidance for Clinical Trial and Routine Practice Use in Canada Clinical Lymphoma Myeloma & Leukemia ·Hira Mian, Alissa Visram, Nana Suwilma, Suzanne Trudel, Annette E. Hay, Richard Leblanc, Michaël Sébag, Rayan Kaedbey, Julie Stakiw, Irwindeep Sandhu, 市川, Philip Kuruvilla, Joey Chou, Graeme Quest, David P. McMullen, M. Garcia-Osuna, Rami Kotb, Christopher P. Venner	2025	0
2	Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre‐autologous stem cell transplant in relapsed/refractory diffuse large B‐cell lymphoma—outcome of rituximab‐dose‐intensive cyclophosphamide, etoposide, cisplatin (R‐DICEP) versus R‐GDP British Journal of Haematology ·Douglas A. Stewart, John Kuruvilla, David M. Lee, 論田中, Neil Chua, ثامري صلاح الدين, Tara Baetz, Mona Shafey, S Graeowska, Sue Robinson, Isabelle Fleury, Graeme Fraser, Carina Ritzmo, Vishal Kukreti, Hasan Şevket KAVUKÇU, Annette E. Hay, Lois E. Shepherd, Bingshu E. Chen, Michael Crump	2024	0
3	Determining the Associations Between Glucocorticoid Use During Hematologic Chemotherapy Treatment and New-onset Diabetes and Hyperglycemia and Mortality: A Population-based Cohort Study Canadian Journal of Diabetes ·Sarah Moore, Monakshi Sawhney, Robyn L. Houlden, Patti A. Groome, 胡景梅, Wenbin Li, Annette E. Hay, Joan Tranmer	2024	1
4	Augmenting clinical trial economic analysis by linking cancer trial data to administrative data: current landscape and future opportunities BMJ Open ·Brooke E. Wilson, Annette E. Hay, Kelvin Chan, Matthew C. Cheung, Timothy P. Hanna	2023	1
5	Comparing the time toxicity of cancer treatments in the CCTG LY.12 trial. Journal of Clinical Oncology ·Arjun Gupta, Annette E. Hay, Michael Crump, Marina Djurfeldt, Liting Zhu, Matthew C. Cheung, Lois E. Shepherd, Bingshu E. Chen, Christopher M. Booth	2023	1
6	Health-related quality of life in early-stage Hodgkin lymphoma: a longitudinal analysis of the ABVD arm in the randomized controlled trial HD.6 Supportive Care in Cancer ·Hira Mian, Jolie Ringash, Ralph M. Meyer, Annette E. Hay, Lois E. Shepherd, Marina Djurfeldt, Jane N. Winter, Jonathan Sussman, Joseph L. Pater, Bingshu E. Chen, Anca Prica	2023	2
7	CCTG LY18‐A phase I master protocol of novel combination therapy for patients with relapsed or refractory lymphoma ‐ the RGDP‐Venetoclax substudy Hematological Oncology ·Sarit Assouline, Diego Villa, Annette E. Hay, Nathalie A. Johnson, Michael Crump, Robert Kridel, Anca Prica, Н.Ю. Пономаренко, Alina S. Gerrie, Kerry J. Savage, H. Higier, Lois E. Shepherd, B. Chen, John Kuruvilla, Isidoro Rodríguez Pérez	2023	1
8	Validating Restricted Mean Survival Time Estimates From Reconstructed Kaplan-Meier Data Against Original Trial Individual Patient Data From Trials Conducted by the Canadian Cancer Trials Group Value in Health ·M. V. Posnov, T. Orimoto, Dongsheng Tu, Joseph L. Pater, Annette E. Hay, Matthew C. Cheung, Kelvin Chan	2022	4
9	Validation, Implementation, and Clinical Impact of the Oncomine Myeloid Targeted-Amplicon DNA and RNA Ion Semiconductor Sequencing Assay Journal of Molecular Diagnostics ·Lívian De Freitas Albuquerque, Ao Li, B Gilles, M. Gómez-Ayechu, Brooke Snetsinger, Xiao Zhang, Roman Tesar, В.Ф. Рапута, Guillaume Richard‐Carpentier, Susan Crocker, David Good, Annette E. Hay, Graeme Quest, Nancy Carson, Harriet Feilotter, Michael J. Rauh	2021	7
10	IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia Leukemia & lymphoma ·Sarit Assouline, Lilian Amrein, Raquel Aloyz, Versha Banerji, Stephen Caplan, Carolyn Owen, Wanda Hasegawa, Sue Robinson, Sudeep Shivakumar, Anca Prica, Anthea Peters, Linda Hagerman, Laura Rodríguez, Zahra Haj Zeinolabedin Eslam, Lawrence Panasci, Bingshu E. Chen, Annette E. Hay	2020	6
11	Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) in the SWOG 1612 Platform Randomized Phase II/III Clinical Trial Blood ·Annette E. Hay, Sarit Assouline, Roland B. Walter, Richard F. Little, Anna Moseley, Franco Greggio, Annie Im, James M. Foran, Jerald P. Radich, Min Fang, Megan Othus, Harry P. Erba, Laura C. Michaelis	2019	7
12	The Economic Impact of the Transition from Branded to Generic Oncology Drugs Current Oncology ·Winson Y. Cheung, Leong L. San, Nicole Mittmann, Natasha B. Leighl, Matthew C. Cheung, Kelvin Chan, Penelope A. Bradbury, Raymond Ng, Abderazzak Lakrim, Keyue Ding, Joseph L. Pater, Dongsheng Tu, Annette E. Hay	2019	18
13	Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study Blood ·Michael Crump, Sattva S. Neelapu, Umar Farooq, Éric Van Den Neste, John Kuruvilla, Jason R. Westin, Brian K. Link, Annette E. Hay, James R. Cerhan, Liting Zhu, Sami Boussetta, Lei Feng, Matthew J. Maurer, Lynn Navale, Jeff Wiezorek, William Y. Go, Christian Gisselbrecht Hit paper breakdown →	2017	1042
14	Comparison of Outcomes By Age of Patients with Limited Stage Hodgkin Lymphoma Treated with ABVD Alone; A Secondary Analysis of the Canadian Cancer Trial Group HD.6 Trial Blood ·Laura Rodríguez‐Romo, Ralph M. Meyer, Joseph L. Pater, Jonathan Sussman, C Roeland, Seralathan Vivekaanathan, Jane N. Winter, T. Vuong, Jason S. McIntosh, Liam Mulroy, Lois E. Shepherd, Marina Djurfeldt, Bingshu E. Chen, Annette E. Hay	2017	1
15	Linkage of Clinical Trial and Administrative Data: A Survey of Cancer Patient Preferences Current Oncology ·Annette E. Hay, Yvonne Leung, Joseph L. Pater, Melissa Brown, Elizabeth Bell, Doris Howell, Zahra Kassam, С Н Хисматова, D. MacFarland, Andrey A Popkov	2017	17
16	Accrual of Adolescents and Young Adults with Cancer to Clinical Trials Current Oncology ·Annette E. Hay, Charlene Rae, Graeme Fraser, Ralph M. Meyer, Fleishman Morosot Jiménez Gómez, Stuart Bevan, Mary L. McBride, Geoff D.E. Cuvelier, 昭二持丸, Ronald D. Barr	2016	18
17	Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12^* Leukemia & lymphoma ·Tara Baetz, Bingshu E. Chen, Stephen Couban, C. Tom Kouroukis, Rena Buckstein, John Kuruvilla, Kang Howson‐Jan, David Szwajcer, Massimo Federico, Ralph M. Meyer, Marina Djurfeldt, Annette E. Hay, Lois E. Shepherd, Michael Crump	2016	8
18	Estimation of Drug Cost Avoidance and Pathology Cost Avoidance through Participation in NCIC Clinical Trials Group Phase III Clinical Trials in Canada Current Oncology ·Patricia A. Tang, Annette E. Hay, Chris J. O’Callaghan, Nicole Mittmann, Carole Chambers, Joseph L. Pater, Natasha B. Leighl	2016	15
19	Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12 Blood ·John Kuruvilla, David MacDonald, C. Tom Kouroukis, Matthew C. Cheung, Harold J. Olney, A. Robert Turner, S Mandgar, Matthew D. Seftel, Katsiaryna Miniukovich, Stefano Luminari, Stephen Couban, Tara Baetz, Ralph M. Meyer, Annette E. Hay, Lois E. Shepherd, Marina Djurfeldt, Syed Sameer Aga, Bingshu E. Chen, Michael Crump	2015	28
20	Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome European Journal of Cancer ·Jose Gerard Monzon, Annette E. Hay, Gail T. McDonald, Joseph L. Pater, Ralph M. Meyer, Eric X. Chen, Bingshu E. Chen, Janet Dancey	2015	19

About Annette E. Hay

Annette E. Hay is a scholar working on Pathology and Forensic Medicine, Hematology, Genetics, Oncology and Statistics and Probability, having authored 82 papers that have together received 1.6k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (33 papers), Economic and Financial Impacts of Cancer (17 papers), Health Systems, Economic Evaluations, Quality of Life (16 papers), Chronic Lymphocytic Leukemia Research (15 papers), Multiple Myeloma Research and Treatments (12 papers), Protein Degradation and Inhibitors (9 papers), Acute Lymphoblastic Leukemia research (9 papers) and CNS Lymphoma Diagnosis and Treatment (8 papers). The work is most often cited by research in Pathology and Forensic Medicine (846 citations), Oncology (1.0k citations), Genetics (232 citations), Immunology (219 citations) and Neurology (154 citations). Annette E. Hay has collaborated with scholars based in Canada, United States and Italy. Frequent co-authors include Michael Crump, John Kuruvilla, Liting Zhu, Christian Gisselbrecht, Éric Van Den Neste, Sami Boussetta, William Y. Go, Lynn Navale, Sattva S. Neelapu and Umar Farooq. Their work appears in journals such as Blood, Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute, Annals of Oncology and The Oncologist.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact